HemCon teams up with Irish institute for antibacterial technology
This article was originally published in Clinica
HemCon has licensed exclusive global rights from the Institute of Technology Sligo, Ireland, for its controlled-release hydrogen peroxide technology. Portland, Oregon-based HemCon plans to research, develop, manufacture and market the technology, which has broad-spectrum antibacterial and antiseptic properties. It can be used in wound and oral care, and has shown promise in early studies of fungal nail infection, which HemCon says has a global market of around $4bn.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.